AR054809A1 - Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa - Google Patents

Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa

Info

Publication number
AR054809A1
AR054809A1 ARP060102823A ARP060102823A AR054809A1 AR 054809 A1 AR054809 A1 AR 054809A1 AR P060102823 A ARP060102823 A AR P060102823A AR P060102823 A ARP060102823 A AR P060102823A AR 054809 A1 AR054809 A1 AR 054809A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkynyl
alkenyl
cycloalkyl
Prior art date
Application number
ARP060102823A
Other languages
English (en)
Inventor
Michael Sotirios Malamas
Ping Zhou
William Floyd Fobare
William Ronald Solvibile
Iwan Suwandi Gunawan
James Joseph Erdei
Yinfa Yan
Patrick Michael Andrae
Dominik Anthony Quagliato
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054809A1 publication Critical patent/AR054809A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente también suministra métodos para el uso de este para inhibir la beta-secretasa (BACE) y tratar depositos beta-amiloides y enmaranamiento neurofibrilar. Reivindicacion 1: Un compuesto de formula (1) en donde W es CO, CS o CH2; X es N, NR, NO, S, SOm, O o CR9; Y es N, NR, NO, S, SOm, O o CR10; Z es C, N, NR, NO, S, SOm, O, CR11 o CR11R12 con la condicion de que procedimiento lo menos uno de X, Y o Z pueden ser, N, NR, NO, S, SOm o O; m es 1 o 2; R es H o un alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8 o un grupo aril alquilo C1-6 cada uno sustituido opcionalmente; R1 y R2 son cada uno independientemente H, COR14, CO2R15 o un grupo alquilo C1-4 opcionalmente sustituidos; R3 es H, OR13 o un grupo alquilo con un C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8 o aril alquilo (C1-6) cada uno sustituido opcionalmente; R4, R5, R9 y R10 son cada una independientemente H, halogeno, NO2, CN, OR14, CO2R15, COR16, NR17R18, SOpNR19R20 o un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-C6, alquinilo o cicloalquilo C3-8 cada uno sustituido opcionalmente; R6 y R8 son cada una independientemente H, halogeno, NO2, CN, OR21, NR22R23 o un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6 o cicloalquilo C3-8 cada uno sustituido opcionalmente; R7 es H, halogeno, NO2, CN, OR24, NR25R26 o un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo o heteroarilo cada uno sustituido opcionalmente; R11, R12, R13, R14, R15, R16, R21, R24, R27, R28 y R29 son cada uno independientemente H o un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloheteroalquilo, o arilo cada uno sustituido opcionalmente; R17, R18, R19, R20, R22, R23, R25, R26, R30, R31, R32 y R33 son cada uno independientemente H, COR34, SOpR35 o un grupo alquilo C1-4, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloheteroalquilo, arilo o heteroarilo cada uno sustituido opcionalmente o R17, R18, o R19, R20, o R22, R23, o R25 R26, o R30, R31, o R32, R33 pueden ser tomados juntos con el átomo al cual ellos están sujetos para formar un anillo de 5 a 7 miembros opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional seleccionado entre O, N, o S; R34 es H, o un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloheteroalquilo, arilo o heteroarilo, cada uno sustituido opcionalmente; y R35 es un grupo alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloheteroalquilo, arilo o heteroarilo, cada uno sustituido opcionalmente; o un tautomero de estos, un estereoisomero de estos o una sal farmacéuticamente aceptable de estos.
ARP060102823A 2005-06-30 2006-06-29 Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa AR054809A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69535305P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
AR054809A1 true AR054809A1 (es) 2007-07-18

Family

ID=37081588

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102823A AR054809A1 (es) 2005-06-30 2006-06-29 Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa

Country Status (12)

Country Link
US (3) US7417047B2 (es)
EP (1) EP1896454A1 (es)
JP (1) JP2009500327A (es)
CN (1) CN101213188A (es)
AR (1) AR054809A1 (es)
AU (1) AU2006266129A1 (es)
CA (1) CA2613045A1 (es)
GT (1) GT200600283A (es)
MX (1) MX2008000213A (es)
PE (1) PE20070189A1 (es)
TW (1) TW200738683A (es)
WO (1) WO2007005366A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006009653A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
AU2005264917A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
MX2007001102A (es) 2004-07-28 2007-04-13 Schering Corp Inhibidores macrociclicos de beta-secretasa.
EP1836208A2 (en) * 2005-01-14 2007-09-26 Wyeth Incoporated AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE
WO2006083760A1 (en) * 2005-02-01 2006-08-10 Wyeth AMINO-PYRIDINES AS INHIBITORS OF β-SECRETASE
JP2008530103A (ja) * 2005-02-14 2008-08-07 ワイス β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
AU2006259573A1 (en) * 2005-06-14 2006-12-28 Pharmacopeia, Inc. Heterocyclic aspartyl protease inhibitors, preparation and use thereof
MX2008000212A (es) * 2005-06-30 2008-03-24 Wyeth Corp Compuestos amino-5-(6 miembros)heteroarilimidazolona y el uso de estos para la modulacion de la (-secretasa.
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
TW200734311A (en) * 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
US20090176850A1 (en) * 2005-11-21 2009-07-09 Astrazeneca Ab Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
CN101360737A (zh) * 2005-12-19 2009-02-04 惠氏公司 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
RU2009100074A (ru) 2006-06-12 2010-07-20 Шеринг Корпорейшн (US) Гетероциклические ингибиторы аспартильной протеазы
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200817406A (en) * 2006-08-17 2008-04-16 Wyeth Corp Imidazole amines as inhibitors of β-secretase
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
CA2662348A1 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of .beta.-secretase
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
WO2008076044A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200831484A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
CL2008000784A1 (es) * 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
CL2008000791A1 (es) * 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
US8653067B2 (en) * 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
TW200902503A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
CA2721738A1 (en) * 2008-04-22 2009-10-29 Schering Corporation Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
BRPI0918449A2 (pt) * 2008-09-11 2019-09-24 Amgen Inc compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
WO2010056194A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
MX2011009571A (es) * 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
US20120015961A1 (en) 2009-03-31 2012-01-19 Shionogi & Co., Ltd. Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TWI488852B (zh) 2009-12-11 2015-06-21 Shionogi & Co 衍生物
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
AU2011227511B2 (en) 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
KR102220259B1 (ko) 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Bace 매개 app 처리과정을 조절하는 히단토인
EP3341362B1 (en) * 2015-08-27 2023-07-05 Nantneuro, LLC Compositions for app-selective bace inhibition and uses therfor
CN113816911B (zh) * 2021-11-24 2022-03-08 季华实验室 一种具有多发光单元的红光材料及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) * 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
DE2901362A1 (de) 1978-01-25 1979-07-26 Sandoz Ag Guanidinderivate, ihre herstellung und verwendung
GB1588096A (en) * 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
ZA967800B (en) 1995-09-20 1997-04-03 Yamanouchi Pharma Co Ltd Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
GB9611046D0 (en) 1996-05-25 1996-07-31 Wivenhoe Techn Ltd Pharmacological compounds
GB2323841A (en) 1997-04-04 1998-10-07 Ferring Bv Group Holdings Pyridine derivatives with anti-tumor and anti-inflammatory activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064396A1 (en) 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
AU2003229024A1 (en) * 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
CN1845919A (zh) 2003-07-01 2006-10-11 拜尔农作物科学有限责任公司 作为杀虫剂的3－吡啶基羧酰胺衍生物
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0417697A (pt) * 2003-12-15 2007-04-03 Schering Corp inibidores de protease de aspartila heterocìclicos
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2005264917A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
WO2006009653A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
EP1836208A2 (en) * 2005-01-14 2007-09-26 Wyeth Incoporated AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE
WO2006083760A1 (en) * 2005-02-01 2006-08-10 Wyeth AMINO-PYRIDINES AS INHIBITORS OF β-SECRETASE
JP2008530103A (ja) * 2005-02-14 2008-08-07 ワイス β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006088694A1 (en) * 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
MX2008000212A (es) 2005-06-30 2008-03-24 Wyeth Corp Compuestos amino-5-(6 miembros)heteroarilimidazolona y el uso de estos para la modulacion de la (-secretasa.
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
JP4780555B2 (ja) * 2005-09-12 2011-09-28 株式会社フジキン 流体制御装置
KR20080050430A (ko) * 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
CN101360737A (zh) * 2005-12-19 2009-02-04 惠氏公司 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
US8826938B2 (en) * 2008-01-22 2014-09-09 Control Components, Inc. Direct metal laser sintered flow control element

Also Published As

Publication number Publication date
US20070004786A1 (en) 2007-01-04
US7417047B2 (en) 2008-08-26
JP2009500327A (ja) 2009-01-08
AU2006266129A1 (en) 2007-01-11
US20100168106A1 (en) 2010-07-01
GT200600283A (es) 2007-02-14
WO2007005366A1 (en) 2007-01-11
AU2006266129A8 (en) 2008-04-17
MX2008000213A (es) 2008-03-24
TW200738683A (en) 2007-10-16
EP1896454A1 (en) 2008-03-12
PE20070189A1 (es) 2007-02-23
CA2613045A1 (en) 2007-01-11
US20080306091A1 (en) 2008-12-11
CN101213188A (zh) 2008-07-02
US7705030B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
ES2196772T3 (es) Compuestos amino ciclicos.
AR064345A1 (es) Derivados de 8-oxoadenina
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR052863A1 (es) Compuestos de quinolina heteroaromaticos
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
AR055774A1 (es) Fenilacetamidas apropiadas como inhibidores de proteina quinasa
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR125304A1 (es) Compuestos de oxazepina acíclicos y usos de los mismos
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR049263A1 (es) Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.

Legal Events

Date Code Title Description
FB Suspension of granting procedure